Ringshausen I - Search Results

1

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.

Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. Christophorou MA, et al. Among authors: ringshausen i. Nature. 2006 Sep 14;443(7108):214-7. doi: 10.1038/nature05077. Epub 2006 Sep 6. Nature. 2006. PMID: 16957739

2

Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.

Evan GI, Christophorou M, Lawlor EA, Ringshausen I, Prescott J, Dansen T, Finch A, Martins C, Murphy D. Evan GI, et al. Among authors: ringshausen i. Cold Spring Harb Symp Quant Biol. 2005;70:263-73. doi: 10.1101/sqb.2005.70.054. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869762 Review.

3

Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.

Ringshausen I, Peschel C, Decker T. Ringshausen I, et al. Curr Drug Targets. 2006 Oct;7(10):1349-59. doi: 10.2174/138945006778559210. Curr Drug Targets. 2006. PMID: 17073597 Review.

4

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Ringshausen I, et al. Cancer Cell. 2006 Dec;10(6):501-14. doi: 10.1016/j.ccr.2006.10.010. Cancer Cell. 2006. PMID: 17157790

5

Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.

Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Häcker G, Goetze K, Oostendorp R, Peschel C, Decker T. Bogner C, et al. Among authors: ringshausen i. Br J Haematol. 2003 Jul;122(2):260-8. doi: 10.1046/j.1365-2141.2003.04438.x. Br J Haematol. 2003. PMID: 12846895

6

Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells.

Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, Peschel C, Decker T. Ringshausen I, et al. Leukemia. 2004 Dec;18(12):1964-70. doi: 10.1038/sj.leu.2403544. Leukemia. 2004. PMID: 15483673

7

Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.

Ringshausen I, Peschel C, Decker T. Ringshausen I, et al. Leuk Lymphoma. 2005 Jan;46(1):11-9. doi: 10.1080/10428190400005353. Leuk Lymphoma. 2005. PMID: 15621776 Review.

8

Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.

Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Hipp S, et al. Among authors: ringshausen i. Haematologica. 2005 Oct;90(10):1433-4. Haematologica. 2005. PMID: 16219581

9

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

Ringshausen I, Oelsner M, Weick K, Bogner C, Peschel C, Decker T. Ringshausen I, et al. Leukemia. 2006 Mar;20(3):514-20. doi: 10.1038/sj.leu.2404113. Leukemia. 2006. PMID: 16437144

10

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T. Wanner K, et al. Among authors: ringshausen i. Br J Haematol. 2006 Sep;134(5):475-84. doi: 10.1111/j.1365-2141.2006.06210.x. Br J Haematol. 2006. PMID: 16856892

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results